Stock Market News
Indivior downgraded to 'neutral' at Citi
Despite a strong run in its shares, Citi still saw potential upside from the delay of generic versions of Indivior's Suboxone beyond 2018, but still warned of "conservatively modelled generic competition".
The entry of Par Pharmaceuticals generic Suboxone film to the market, as a result of the legal settlement which allows the rival to begin selling its version on 1 January 2023, or earlier under certain unspecified circumstances, remains somewhat uncertain.
However, the bank felt that a launch "at risk" was unlikely following the appeal lodged by Indivior against a group of drug companies to settle litigation over patent infringement of its Suboxone opioid addiction treatment.
Nonetheless, it noted that the company's valuation was "highly sensitive" to peak sales assumptions for the opioid addiction product, which was launched in February.
Indeed, a delay to 2023 would give 109p of upside, on its estimates, Citi said.
The broker also noted that the success of the Sublocade roll out "is key to the company's future", although the success of that roll-out would not be known until the second quarter.
"With IMS data not fully captured, tracking the success of the launch will be difficult and investors will have to wait until 2Q18 results for reported sales and key performance indicators," Citi's analysts said as they downgraded their stance on Indivior to 'neutral' from 'buy' and issued it with a 500p target price.
The entry of Par Pharmaceuticals generic Suboxone film to the market, as a result of the legal settlement which allows the rival to begin selling its version on 1 January 2023, or earlier under certain unspecified circumstances, remains somewhat uncertain.
However, the bank felt that a launch "at risk" was unlikely following the appeal lodged by Indivior against a group of drug companies to settle litigation over patent infringement of its Suboxone opioid addiction treatment.
Nonetheless, it noted that the company's valuation was "highly sensitive" to peak sales assumptions for the opioid addiction product, which was launched in February.
Indeed, a delay to 2023 would give 109p of upside, on its estimates, Citi said.
The broker also noted that the success of the Sublocade roll out "is key to the company's future", although the success of that roll-out would not be known until the second quarter.
"With IMS data not fully captured, tracking the success of the launch will be difficult and investors will have to wait until 2Q18 results for reported sales and key performance indicators," Citi's analysts said as they downgraded their stance on Indivior to 'neutral' from 'buy' and issued it with a 500p target price.
Related share prices |
---|
Indivior (INDV) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price